Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo
NCT01401374
Autoimmune Diseases, Endocrine System Diseases
New York, United States
View Trial DetailsNCT Number: NCT01206374
Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.
Looking for future studies?
Notify MeAll sexes
Observational
Department of Dermatology, Beth Israel Medical Center, New York, United States
Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: point prevalence
dermatology life quality indices were you used and correlated with location of disease
Time frame: single survey
Correlation of the patient survey response with chart documentation was performed.
St. Luke's-Roosevelt Hospital Center
Other
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01401374
Autoimmune Diseases, Endocrine System Diseases
New York, United States
View Trial DetailsNCT00907062
Hypopigmentation, Pigmentation Disorders
Mississauga, Ontario, Canada
View Trial DetailsNCT00372307
Hypopigmentation, Pigmentation Disorders
Ghent, Belgium
View Trial DetailsNCT07557693
Hypopigmentation, Pigmentation Disorders
Nice, Alpes-maritimes, France
View Trial Details